IL-12 pDNA adjuvant

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV InfectionsTherapeutic Vaccine

Phase 1

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

CompletedNCT01578889

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2012-05-31End: 2016-10-31Updated: 2021-10-15

Therapeutic Vaccine for HIV

CompletedNCT01859325

National Institute of Allergy and Infectious Diseases (NIAID)HIV, Therapeutic Vaccine

Start: 2013-05-10End: 2017-02-26Updated: 2020-03-03

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

CompletedNCT03181789

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-10-18End: 2020-04-29Updated: 2024-02-07

Related Papers

Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119

JCI Insight2024-08-015 citations

HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption.

2020-07-165 citations

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

2018-09-2049 citations

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 <sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNA

Clinical and Vaccine Immunology2017-09-2145 citations